GHK-Cu Dosage in Research Protocols: Concentrations, Routes, and Pharmacokinetics

The concentrations studied, plainly

GHK-Cu has been tested across a wide range of concentrations depending on what was being studied and how it was delivered. In cell culture models, it acts at picomolar to nanomolar amounts — very small. Human clinical trials used topical formulations ranging from roughly 0.02% up to a 50–100 mg/mL spray for hair loss.

Animal studies used systemic routes (intraperitoneal injection, intranasal, oral gavage) at much higher amounts per body weight — these are rodent research doses and are not human recommendations.

The figures on this page are the concentrations documented in the published research. GHK-Cu is not FDA-approved as a drug for any indication. The numbers describe what researchers studied, not what any person should use.

Concentrations Studied in GHK-Cu Research

GHK-Cu has been studied at a range of concentrations across different experimental contexts. The following summarizes published research doses, not human use recommendations.

Cell culture models: Collagen stimulation in human dermal fibroblasts was studied at 10^-12 to 10^-9 M (picomolar to nanomolar range), with maximum effect at 10^-9 M ^[1]. Keratinocyte and epidermal stem cell models have been studied at 0.1–10 micromolar ^[5]. MMP/TIMP modulation in rat dermal fibroblasts was demonstrated at nanomolar concentrations ^[2].

Animal models — systemic: The mouse emphysema study administered GHK-Cu at 0.2, 2, and 20 microg/g/day via intraperitoneal injection on alternate days for 12 weeks ^[12]. Aged mouse cognitive studies used systemic administration (dose not specified in available reviews) ^[10].

Animal models — topical: The ionic liquid microemulsion hair study in mice used a formulated topical microemulsion (CaT-ME) at an unspecified mass concentration ^[8]. Liposomal GHK-Cu was applied as a topical wound dressing in mouse scald models ^[20]. The photo-crosslinked hyaluronic acid hydrogel wound study used GHK-C16 peptide nanofibers at formulation-loading concentrations ^[13].

Human clinical trials:

• Hair loss RCT (Lee et al. 2016): topical spray at 50 mg/mL and 100 mg/mL, once daily for 6 months ^[7].
• Skin aging studies (Leyden et al. 2015): topical cream and serum applied twice daily for 8–12 weeks; specific concentration not disclosed but within the 0.02–5% cosmetic formulation range ^[3].
• Skin collagen study (Pickart et al. 2015): topical formulation at unspecified concentration for 12 weeks ^[5].

Clinical trials with pre-registered protocols: NCT07437586 (CuHeal: Topical GHK-Cu Gel for Acute Skin Wound Healing) is registered at ClinicalTrials.gov and ongoing as of 2026. This represents the most rigorous prospective human wound-healing protocol for GHK-Cu to date.

GHK-Cu Half-Life and Pharmacokinetics

GHK-Cu is an unmodified tripeptide, and its systemic pharmacokinetics are shaped by this molecular simplicity.

Plasma half-life: Approximately 25–35 minutes in rodent pharmacokinetic models for intravenous administration. Rapid peptidase degradation and renal filtration account for the short systemic half-life ^[18].

Topical route: Creates a skin depot effect. Local tissue concentrations remain elevated for hours beyond what systemic circulation would sustain, because the peptide is not rapidly cleared from the stratum corneum and dermis once deposited ^[18]. This is the pharmacokinetic rationale for topical application despite the short plasma half-life — the target tissue is the site of application.

Subcutaneous route: Produces sustained low-level serum exposure over 6–8 hours; bioavailability estimated at 85–95% in rodent models ^[18]. This is the most studied non-topical route for research purposes.

Intraperitoneal route (animal models only): Used in the emphysema and cognitive aging studies; not directly relevant to human administration contexts ^[10][12].

Oral route: Limited bioavailability — estimated 15–25% in rodent models — due to gastric acid degradation and first-pass hepatic metabolism ^[18]. The tripeptide is susceptible to digestive proteases; oral delivery requires protective formulation strategies to achieve meaningful systemic exposure.

Formulation stability notes: GHK-Cu is pH-sensitive — strong acids (AHAs, BHAs, vitamin C at low pH) reduce peptide stability. Palmitoylation and copper complexation improve stability and penetration in topical formulations. The locked partition coefficient (-2.24) limits passive skin permeation regardless of concentration ^[18].

Routes Studied in GHK-Cu Research

The published research covers four administration routes, each with distinct pharmacokinetic profiles and evidence quality:

1. Topical (cream, serum, spray, hydrogel, liposome, nanoparticle): The most clinically studied route. Human trial data exists for topical application (collagen studies, hair RCT, wound healing trial NCT07437586). Penetration is limited by the peptide's hydrophilicity; advanced delivery systems (liposomes, microneedles, ionic liquid microemulsions) improve penetration but data remains incomplete for some formulation types ^{[8][18][20][21]}.

1. Subcutaneous injection: 85–95% bioavailability in rodent models; serum detection over 6–8 hours ^[18]. No published human subcutaneous GHK-Cu trials as of this review.

1. Intraperitoneal (animal models only): Used in the emphysema ^[12] and cognitive aging ^[10] mouse studies; not a clinically relevant route for human context.

1. Oral: Limited data; bioavailability estimated 15–25% in rodents ^[18]. The fragility of unmodified tripeptides in the GI environment makes this route challenging without protective formulation.

For detailed GHK-Cu dosage in research protocols comparisons, refer to the table below and the peer-reviewed references.

Research-context summary table: